At virtually any American gas station, a scan of the counter near the register reveals more than just candy and beef jerky. Colorful packages of gummies, tablets, and drink bottles labeled “kratom” sit alongside sports drinks in the refrigerated section. Many tout “natural” or “organic” claims, but these products often contain concentrated, lab-made synthetic opioids that are far more potent than the plant itself.
Natural kratom comes from a tree native to Southeast Asia, where people have chewed or brewed its leaves for centuries. But today, manufacturers are extracting the active compounds and chemically altering them into substances like 7-OH and MGPI, which the FDA has called opioids more powerful than morphine. These lab-modified versions carry a high risk of addiction and overdose, and they are being sold through the same retail channels that once peddled synthetic drugs like K2 and Spice.
What’s particularly alarming is the lack of oversight. In 15 states, there are currently no regulations on these kratom opioids, meaning a teenager can walk into a neighborhood store and buy them without any age check. The packaging, often bright and cartoonish, can be especially appealing to young people.
United Against Fentanyl, an organization founded by families who have lost children to fentanyl, is now turning its attention to kratom. “Our most difficult challenge has never been sharing the facts about fentanyl,” said Richard Baum, a former acting director of the White House Office of National Drug Control Policy and a board member of the group. “However, many families are not aware that another opioid is today legally available to their kids at neighborhood gas stations and vape shops.”
Baum and Paul Martin, who leads Kratom Watch and is the CEO of United Against Fentanyl, draw parallels to past crises. “We have seen this before,” they write. “A new product arrives at local retail stores. The name seems harmless — spice, K2, bath salts. They are cheap and easy to buy, and someone in a teen’s circle of friends may have already tried them. At first, there are few signs of trouble. But over time, they lead to addiction, overdose and even death.”
Data from U.S. poison control centers show a 1,200 percent increase in kratom-related reports from 2015 to 2025, including 233 deaths. The DEA has taken notice: in October, it issued a notice of intent to place concentrated 7-OH and MGPI into Schedule I, the most restrictive category. That final order could take effect this month, but advocates argue it’s not enough.
Legislation known as the End Gas Station Heroin Act would ban concentrated 7-OH and MGPI, but crucially, it would also cover any other synthetic or semi-synthetic opioid more potent than morphine. “Banning a whole class of drugs based on their physiological effects, instead of an endless game of chemical whack-a-mole, helps the nation get ahead of the next threat,” the authors argue. The bill would not affect unaltered kratom leaf or punish possession, but would target the stronger synthetic offshoots causing the most harm.
In the meantime, states can act by setting strict age and potency limits. Store owners can pull these products from shelves. Parents can talk to their children about the risks. “The reality is that kratom opioids are harmful,” Baum and Martin write. “Families suffered when we were slow to act on other dangerous drugs. Let us not make that mistake again with kratom.”
